This randomized controlled trial compares the combination of low-dose aspirin plus low molecular weight heparin (LMWH) versus aspirin alone for the prevention of preeclampsia in gravidas at high risk. The premise is that aspirin begun in the first trimester reduces preeclampsia risk in high-risk individuals, whereas LMWH may confer additional benefit through anticoagulant, anti-inflammatory, and endothelial protective mechanisms.
Evidence to date regarding the incremental value of adding LMWH to aspirin remains limited and inconsistent, hence the current study seeks to clarify whether combined therapy lowers the incidence of preeclampsia compared with aspirin monotherapy. Key design and status notes: the trial is interventional with a primary prevention aim, enrolling high-risk pregnant individuals.
It estimates enrolling 100 participants and is currently in the recruiting phase with completion anticipated in July 2027. The study is categorized under critical care concerns related to hypertensive disorders of pregnancy, including preeclampsia and gestational hypertension, and involves agents including tinzaparin as the LMWH component.
ClinicalTrials.gov published a clinical update in Critical Care on 23 Jan 2026.
The item focuses on LDA and LMWH vs LDA Alone in High-risk Patients for Preeclampsia Prevention.
Review the original article for the full source wording and details.